Stock GLUE MONTE ROSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Monte Rosa Therapeutics, Inc.

Equities

GLUE

US61225M1027

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
4.16 USD +4.26% Intraday chart for Monte Rosa Therapeutics, Inc. -20.00% -26.37%
May. 16 Sector Update: Health Care Stocks Mixed in Late Afternoon Trading MT
May. 16 Monte Rosa Therapeutics Prices $100 Million Public Offering MT

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating
MT
Wedbush Starts Monte Rosa Therapeutics With Outperform Rating, $11 Price Target
MT
Credit Suisse Trims Monte Rosa Therapeutics' Price Target to $11 From $12, Keeps Neutral Rating
MT
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight From Equalweight, Price Target at $18
MT
UBS Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $22 Price Target
MT
Jefferies Starts Monte Rosa Therapeutics at Buy With $20 Price Target
MT
Piper Sandler Adjusts Price Target on Monte Rosa Therapeutics to $21 From $40, Reiterates Overweight Rating
MT
Credit Suisse Initiates Monte Rosa Therapeutics at Neutral, $19 Price Target
MT
Berenberg Bank Adjusts Monte Rosa Therapeutics' Price Target to $28 From $32, Maintains Buy Rating
MT
Wells Fargo Starts Monte Rosa Therapeutics at Equalweight With $19 Price Target
MT
Guggenheim Adjusts Price Target for Monte Rosa Therapeutics to $35 From $40, Maintains Buy Rating
MT
Berenberg Bank Initiates Coverage on Monte Rosa Therapeutics With Buy Rating, $32 Price Target
MT
MONTE ROSA THERAPEUTICS : SVB Leerink Starts Monte Rosa Therapeutics at Market Perform with $20 Price Target
MT
MONTE ROSA THERAPEUTICS : JPMorgan Initiates Monte Rosa Therapeutics at Overweight Rating With $38 Price Target
MT
MONTE ROSA THERAPEUTICS : Cowen Initiates Coverage on Monte Rosa Therapeutics With Outperform Rating
MT
MONTE ROSA THERAPEUTICS : Piper Sandler Starts Monte Rosa Therapeutics at Overweight With $40 Price Target
MT
MONTE ROSA THERAPEUTICS : Guggenheim Starts Monte Rosa Therapeutics at Buy With $30 Price Target
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLUE Stock
  4. News Monte Rosa Therapeutics, Inc.
  5. Analyst Reco.